Buchumschlag

Neue Behandlungsoptionen bei Gliomen = New treatment options for gliomas

BackgroundPatients with gliomas in molecularly defined subgroups (isocitrate dehydrogenase, IDH mutation, 1p/19q codeletion) already benefit now from standard treatments. The O6-methylguanine DNA-methyltransferase (MGMT) is the only relevant biomarker for treatment decisions for or against alkylatin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Wick, Wolfgang (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Deutsch
Englisch
Veröffentlicht: 2019
In: Der Onkologe
Year: 2018, Jahrgang: 25, Heft: 1, Pages: 60-66
ISSN:1433-0415
DOI:10.1007/s00761-018-0479-8
Online-Zugang:Verlag, Volltext: https://doi.org/10.1007/s00761-018-0479-8
Volltext
Verfasserangaben:Wolfgang Wick

MARC

LEADER 00000caa a2200000 c 4500
001 1669574636
003 DE-627
005 20251025154125.0
007 cr uuu---uuuuu
008 190722r20192018xx |||||o 00| ||ger c
024 7 |a 10.1007/s00761-018-0479-8  |2 doi 
035 |a (DE-627)1669574636 
035 |a (DE-599)KXP1669574636 
035 |a (OCoLC)1341234116 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a ger  |a eng 
084 |a 33  |2 sdnb 
100 1 |a Wick, Wolfgang  |d 1970-  |e VerfasserIn  |0 (DE-588)120297736  |0 (DE-627)080586929  |0 (DE-576)186221320  |4 aut 
245 1 0 |a Neue Behandlungsoptionen bei Gliomen  |b  = New treatment options for gliomas  |c Wolfgang Wick 
246 3 1 |a New treatment options for gliomas 
264 1 |c 2019 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 22.07.2019 
520 |a BackgroundPatients with gliomas in molecularly defined subgroups (isocitrate dehydrogenase, IDH mutation, 1p/19q codeletion) already benefit now from standard treatments. The O6-methylguanine DNA-methyltransferase (MGMT) is the only relevant biomarker for treatment decisions for or against alkylating chemotherapy.PurposeIn the present review article new concepts of immunotherapy and targeted approaches as well as treatment with electrical fields for gliomas are discussed.ResultsIn recent years there have been efforts to develop study concepts with molecular targeted treatment for patients with gliomas harboring IDH mutations, endothelial growth factor receptor (EGFR) overexpression, EGFRv3 expression and also other defined molecular alterations in tumor tissue. Current treatment studies transfer these to studies involving single biomarkers in so-called modern umbrella designs. In these umbrella concepts a single disease entity is treated in different study groups with molecular targeted treatments based on molecular biomarker tests. Key outcomes of these trials are not only patients who benefit but also information on sensitivity or resistance mechanisms of the examined treatments. Similar trials are being designed for immunotherapies with variable approaches involving checkpoint inhibition on the one side and different vaccination approaches including the use of chimeric antigen receptor (CAR) cells on the other.ConclusionAlternating electrical fields are a therapeutic option available for patients with newly diagnosed glioblastoma after successful completion of chemoradiation. 
534 |c 2018 
650 4 |a Brain tumors 
650 4 |a EGFRv3 expression 
650 4 |a EGFRvIII-Expression 
650 4 |a Hirntumoren 
650 4 |a IDH mutations 
650 4 |a IDH-Mutationen 
650 4 |a Immunotherapy 
650 4 |a Immuntherapie 
650 4 |a Präzisionsmedizin 
650 4 |a Precision medicine 
773 0 8 |i Enthalten in  |t Der Onkologe  |d Berlin : Springer, 1996  |g 25(2019), 1, Seite 60-66  |h Online-Ressource  |w (DE-627)254638546  |w (DE-600)1462966-5  |w (DE-576)074531522  |x 1433-0415  |7 nnas  |a Neue Behandlungsoptionen bei Gliomen = New treatment options for gliomas 
773 1 8 |g volume:25  |g year:2019  |g number:1  |g pages:60-66  |g extent:7  |a Neue Behandlungsoptionen bei Gliomen = New treatment options for gliomas 
856 4 0 |u https://doi.org/10.1007/s00761-018-0479-8  |x Verlag  |x Resolving-System  |3 Volltext 
951 |a AR 
992 |a 20190722 
993 |a Article 
994 |a 2019 
998 |g 120297736  |a Wick, Wolfgang  |m 120297736:Wick, Wolfgang  |d 910000  |d 911100  |e 910000PW120297736  |e 911100PW120297736  |k 0/910000/  |k 1/910000/911100/  |p 1  |x j  |y j 
999 |a KXP-PPN1669574636  |e 3495584757 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"title_sort":"Neue Behandlungsoptionen bei Gliomen","title":"Neue Behandlungsoptionen bei Gliomen","subtitle":" = New treatment options for gliomas"}],"language":["ger","eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 22.07.2019"],"origin":[{"dateIssuedDisp":"2019","dateIssuedKey":"2019"}],"relHost":[{"disp":"Neue Behandlungsoptionen bei Gliomen = New treatment options for gliomasDer Onkologe","physDesc":[{"extent":"Online-Ressource"}],"recId":"254638546","type":{"media":"Online-Ressource","bibl":"periodical"},"language":["ger"],"note":["Gesehen am 18.02.04","Ungezählte Beil.: Supplement"],"id":{"eki":["254638546"],"issn":["1433-0415"],"zdb":["1462966-5"]},"part":{"issue":"1","extent":"7","text":"25(2019), 1, Seite 60-66","pages":"60-66","volume":"25","year":"2019"},"title":[{"subtitle":"Organ der Deutschen Krebsgesellschaft e.V.","title_sort":"Onkologe","title":"Der Onkologe"}],"origin":[{"publisher":"Springer","publisherPlace":"Berlin ; Heidelberg ; New York","dateIssuedKey":"1996","dateIssuedDisp":"1996-2022"}],"pubHistory":["Nachgewiesen 2.1996,3 - Volume 28, issue 4, (April 2022)"]}],"person":[{"display":"Wick, Wolfgang","family":"Wick","given":"Wolfgang","role":"aut"}],"titleTranslated":[{"translated":"New treatment options for gliomas"}],"recId":"1669574636","physDesc":[{"extent":"7 S."}],"id":{"doi":["10.1007/s00761-018-0479-8"],"eki":["1669574636"]},"name":{"displayForm":["Wolfgang Wick"]}} 
SRT |a WICKWOLFGANEUEBEHAND2019 

Ähnliche Einträge